ST266
Sponsors
Noveome Biotherapeutics, formerly Stemnion
Conditions
Allergic ConjunctivitisBurnsCytokine Release SyndromeDiabetesDry Eye SyndromeNecrotizing EnterocolitisPeriodontal DiseasePersistent Corneal Epithelial Defect
Phase 1
ST266 Versus Standard Care In Treating Partial Thickness Burns
TerminatedNCT00886470
Start: 2009-06-30End: 2010-03-31Updated: 2019-05-15
Study of ST266 Versus Saline in Treating Skin Irritation From Radiation
CompletedNCT01714973
Start: 2012-10-31End: 2015-10-31Updated: 2019-05-13
Study of ST266 Eye Drops in Treating Dry Eye
CompletedNCT02369861
Start: 2015-03-31End: 2015-12-31Updated: 2019-05-13
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
CompletedNCT04720378
Start: 2021-05-30End: 2022-05-03Updated: 2022-06-15
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
RecruitingNCT06315738
Start: 2024-08-19End: 2029-11-01Target: 36Updated: 2026-04-13
Phase 2
Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts
TerminatedNCT01715012
Start: 2012-10-31End: 2015-03-31Updated: 2019-05-15
Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis
CompletedNCT02761993
Start: 2016-04-30End: 2017-10-31Updated: 2021-07-22
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
CompletedNCT02978183
Start: 2016-12-31End: 2017-11-30Updated: 2023-04-10
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
CompletedNCT03687632
Start: 2019-06-10End: 2020-08-25Updated: 2021-08-18
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
TerminatedNCT05066698
Start: 2022-04-27End: 2022-09-07Updated: 2022-10-25